BioInformant

Your Global Leader in Stem Cell Market Research

Home » Exosomes » Page 3

MDimune Collaborating with Paracelsus Medical University for EV Therapeutics

By

Seoul, Korea, Apr 30, 2020 — MDimune Inc., a cell-derived vesicle (CDVs)-based therapeutics company with BioDrone® platform technology, announced on April 30th, 2020, the signature of a research collaboration agreement with Paracelsus Medical University (PMU, Salzburg, Austria). PMU will bring their experience to further the company’s global development goals.

Those in attendance from PMU were Herbert Resch, Professor and Rector; Michael Nake, Chancellor; Eva Rohde, Professor, Vice Rector and Director of GMP laboratory; and Mario Gimona, Associate Professor and Head of Production GMP. Those in attendance from MDimune were Shin Gyu Bae, Chief Executive Officer; Seung Wook Oh, Chief Scientific Officer; Tae Kee Jeong, Chief Financial Officer; and Hui-Chong Lau, Manager of the CMC team.

The agreement states that PMU will develop a process for producing CDV therapeutics at GMP-compliant scale as well as supply them for the pre-clinical study and the initial phase of human clinical study. PMU has also agreed to establish GMP-grade mesenchymal stem cell banks derived from umbilical cords for MDimune, which will then be used to produce CDVs required for various preclinical and clinical development. [Read more…]

First Dosing in Plexoval Exosome Wound Healing Human Study

By

Highlights

  • First human dosing of Plexaris™ has occurred in Exopharm’s PLEXOVAL Study
  • PLEXOVAL is a world-first study using a cell free, platelet-derived exosome product manufactured using Exopharm’s proprietary LEAP Technology for wound healing
  • Other pre-clinical development progress will be reported over coming months

MELBOURNE, Australia – Jan. 29, 2020 11:00 UTC — Regenerative medicine company Exopharm Limited (ASX:EX1) announces first dosing has occurred in the PLEXOVAL Phase I study using exosomes isolated from human platelets for wound healing, Exopharm’s first human clinical trial. Further participants are expected to soon follow in this study that involves up to 20 participants. [Read more…]

Aegle Therapeutics Raises $4M to Fund First Trial in the U.S. Using Exosomes from Allogeneic MSCs

By

Aegle Therapeutics raises $4 million to fund a groundbreaking stem cell exosome clinical trial to treat the orphan disease, Dystrophic Epidermolysis Bullosa.

BOSTON and MIAMI, Jan. 7, 2020 — Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal stem cells as therapy, announced the closing of a $4M financing. Aegle’s platform technology is initially being developed to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric skin blistering disorder.  [Read more…]

Market Forces Driving Growth of the Exosome Industry

By

Market forces driving growth of the exosome have been expanding over the past two years, with increasing investment flowing into the space, merger and acquisition (M&A) activity accelerating, and new therapeutics entering various stages of development. Exosomes are defined as small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. They are made in some form by all species, including bacteria that produce analogous outer membrane vesicles (OMC). [Read more…]

Stem Cell Medicine Manufacturing MSC-Derived Exosomes for Treatment of Autism

By

With autism spectrum disorder (ASD) affecting between 1-2% of the population and affecting all racial, ethnic, and socioeconomic groups, the condition is becoming of global importance. While the pharma industry has not yet been able to deliver a solution for this disease, the cell therapy industry is now undertaking the challenge. [Read more…]

BioInformant's World-Class Clients